• NewAmsterdam Pharma raises $196m through Series A funding round pharmaceutical-technology
    January 18, 2021
    Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib.
PharmaSources Customer Service